Follow Slashdot stories on Twitter


Forgot your password?
Back for a limited time - Get 15% off sitewide on Slashdot Deals with coupon code "BLACKFRIDAY" (some exclusions apply)". ×
Medicine Science

HIV Vaccine Safe Enough To Pass Phase 1 Human Trials 141

An anonymous reader sends this excerpt from Western University in Canada: "The first human applied clinical study (SAV CT 01) using a genetically modified killed whole-virus vaccine (SAV001-H) to evaluate its safety and tolerability was initiated in March 2012. This study is a randomized, observer-blinded, placebo-controlled study of killed whole HIV-1 vaccine (SAV001-H) following intramuscular (IM) administration. Infected men and women, 18-50 years of age, have been enrolled in this study and randomized into two treatment groups to administer killed whole HIV-1 vaccine (SAV001-H) or placebo. Sumagen announced today the patient enrollment has progressed smoothly and there have been no adverse effects observed including local reactions, signs/symptoms and laboratory toxicities after SAV001-H injection in all enrolled patients to date. With these interim results, the SAV001-H has proven safety and tolerability in humans and given Sumagen confidence for the next clinical trials to prove its immunogenicity and efficacy evaluation."
This discussion has been archived. No new comments can be posted.

HIV Vaccine Safe Enough To Pass Phase 1 Human Trials

Comments Filter:

Never say you know a man until you have divided an inheritance with him.